Evidence map›Paper›PMID 37034641›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial.

Angela R Branche, Nadine G Rouphael, Cecilia Losada, Lindsey R Baden, Evan J Anderson, Anne F Luetkemeyer, David J Diemert, Patricia L Winokur, Rachel M Presti, Angelica C Kottkamp and 26 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors.

Angela R BrancheUniversity of Rochester VTEU, Rochester, NY.
Nadine G RouphaelEmory University Hope Clinic, Decatur, GA.
Cecilia LosadaEmory University Hope Clinic, Decatur, GA.
Lindsey R BadenBrigham and Women's Hospital, Harvard Medical School, Boston, MA.
Evan J AndersonCenter for Childhood Infections and Vaccines (CCIV) of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA.
Anne F LuetkemeyerZuckerberg San Francisco General, University of California San Francisco, San Francisco, CA.
David J DiemertGeorge Washington Vaccine Research Unit, George Washington University, Washington D.C.
Patricia L WinokurUniversity of Iowa College of Medicine, Iowa City, IA.
Rachel M PrestiWashington University School of Medicine, St. Louis, MO.
Angelica C KottkampNYU VTEU Manhattan Research Clinic at NYU Grossman School of Medicine, New York, NY.
Ann R FalseyUniversity of Rochester VTEU, Rochester, NY.
Sharon E FreySaint Louis University, Center for Vaccine Development, St. Louis, MO.
Richard RuppUniversity of Texas Medical Branch, Galveston, TX.
Martín BäckerNYU VTEU Long Island Research Clinic at NYU Long Island School of Medicine, Mineola, NY.
Richard M NovakUniversity of Illinois at Chicago-Project WISH, Chicago, IL.
Emmanuel B WalterDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC.
Lisa A JacksonKaiser Permanente Washington Health Research Institute, Seattle, WA.
Susan J LittleDepartment of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA.
Lilly C ImmergluckMorehouse School of Medicine, Atlanta, GA.
Siham M MahgoubHoward University College of Medicine, Howard University Hospital, Washington D.C.
Jennifer A WhitakerDepartments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX.
Tara M BabuDepartments of Medicine, Epidemiology, and Laboratory Medicine & Pathology, University of Washington, Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA.
Paul A GoepfertUniversity of Alabama at Birmingham, Birmingham, AL.
Dahlene N FuscoTulane University School of Medicine, New Orleans, LA.
Robert L AtmarDepartments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX.
Christine M PosavadIDCRC Laboratory Operations Unit - Fred Hutchinson Cancer Center and University of Washington, Seattle, WA.
Antonia NetzlCentre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, UK.
Derek J SmithCentre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, UK.
Kalyani TeluThe Emmes Company, LLC, Rockville, MD.
Jinjian MuThe Emmes Company, LLC, Rockville, MD.
Mat MakowskiThe Emmes Company, LLC, Rockville, MD.
Mamodikoe K MakheneDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Crandon SonjaDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
David C MontefioriDuke University, Durham, NC.
Paul C RobertsDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
John H BeigelDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Statistical Data Coordinating Center: Monkeypox Clinical Research Support75N93021C00012 · NIAID · THE EMMES COMPANY, LLC · PI EWELL, MARIAN · 2021 to 2025
$150.3M
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2M
Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component A: Vaccine Center75N93019C00050 · NIAID · DUKE UNIVERSITY · PI MOODY, TONY · 2019 to 2025
$69.1M
NCI NIH HHS 75N91019D00024NIAID NIH HHS 75N93019C00050NIAID NIH HHS 75N93021C00012NIAID NIH HHS UM1 AI148684Wellcome Trust
6 · The paper itself

Abstract

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent SARS-CoV-2 mRNA vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wildtype spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.

Identifiers

PMID37034641
PMCPMC10081431

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.